Thomas Lackner - APELLIS PHARMACTDL Senior Vice President Head of Europe
| 1JK Stock | EUR 31.28 0.82 2.55% |
Insider
Thomas Lackner is Senior Vice President Head of Europe of APELLIS PHARMACTDL 0001 since 2019.
| Age | 51 |
| Tenure | 5 years |
| Phone | 617 977 5700 |
| Web | http://www.apellis.com |
APELLIS PHARMACTDL Management Efficiency
The company has return on total asset (ROA) of (0.4647) % which means that it has lost $0.4647 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (5.0711) %, meaning that it generated substantial loss on money invested by shareholders. APELLIS PHARMACTDL's management efficiency ratios could be used to measure how well APELLIS PHARMACTDL manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | INSIDER Age | ||
| Jan Harrit | PARKEN Sport Entertainment | 58 | |
| Jacob Lauesen | PARKEN Sport Entertainment | 42 | |
Management Performance
| Return On Equity | -5.07 | |||
| Return On Asset | -0.46 |
APELLIS PHARMACTDL 0001 Leadership Team
Elected by the shareholders, the APELLIS PHARMACTDL's board of directors comprises two types of representatives: APELLIS PHARMACTDL inside directors who are chosen from within the company, and outside directors, selected externally and held independent of APELLIS. The board's role is to monitor APELLIS PHARMACTDL's management team and ensure that shareholders' interests are well served. APELLIS PHARMACTDL's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, APELLIS PHARMACTDL's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Sullivan, Chief Financial Officer, Treasurer | ||
| Nicole Perry, Vice President - Finance | ||
| Adam Townsend, Chief Commercial Officer | ||
| Alec Machiels, Independent Director | ||
| Thomas Lackner, Senior Vice President Head of Europe | ||
| Paul Fonteyne, Independent Director | ||
| A Dunlop, Independent Director | ||
| Stephanie OBrien, Independent Director | ||
| Cedric Francois, President, Chief Executive Officer, Co-Founder, Director | ||
| Gerald Chan, Independent Chairman of the Board | ||
| David Watson, General Counsel, Vice President of Corporate Development | ||
| Victoria Brown, Senior Vice President Program Team Lead – Systemic Chronic | ||
| Pascal Deschatelets, Co-Founder, Chief Operating Officer | ||
| Federico Grossi, Chief Medical Officer | ||
| Lukas Scheibler, Chief Innovation Officer |
APELLIS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is APELLIS PHARMACTDL a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.07 | |||
| Return On Asset | -0.46 | |||
| Operating Margin | (4.60) % | |||
| Shares Outstanding | 110.58 M | |||
| Shares Owned By Insiders | 15.32 % | |||
| Shares Owned By Institutions | 89.16 % | |||
| Revenue | 113.05 M | |||
| Gross Profit | (253.92 M) | |||
| EBITDA | (518.43 M) | |||
| Net Income | (460.28 M) |
Currently Active Assets on Macroaxis
Other Information on Investing in APELLIS Stock
APELLIS PHARMACTDL financial ratios help investors to determine whether APELLIS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in APELLIS with respect to the benefits of owning APELLIS PHARMACTDL security.